News

Terns Pharmaceuticals Welcomes Andrew Gengos as CFO to Drive Growth

Terns Pharmaceuticals Welcomes Andrew Gengos as CFO to Drive Growth

Leadership Change at Terns Pharmaceuticals

Terns Pharmaceuticals, Inc. (NASDAQ: TERN), a clinical-stage biopharmaceutical company focused on developing small-molecule candidates for serious diseases, has announced a significant leadership addition. The Company has appointed Andrew Gengos as its new Chief Financial Officer, effective immediately. This exciting move comes at a pivotal time as Terns continues to innovate in areas such as oncology and obesity treatment.

Andrew Gengos: A Valuable Addition

In welcoming Gengos to the team, Amy Burroughs, the Chief Executive Officer of Terns Pharmaceuticals, expressed her enthusiasm. Burroughs believes that Andrew's vast experience and strong leadership skills will play a critical role in furthering Terns' mission to create impactful medicines that enhance patient lives. With Gengos onboard, the Company anticipates positive changes in its financial strategy that could propel its ambitious projects.

Comments from the New CFO

Mr. Gengos shared his excitement about joining Terns, highlighting the Company's leading programs in oncology and obesity. He expressed his eagerness to collaborate with the existing leadership to strengthen Terns' financial foundation and expand its capacity to deliver innovative treatments. Gengos brought to the table over 25 years of extensive finance and corporate strategy experience in the life sciences and biotechnology sectors, an asset that will be invaluable as Terns pushes forward with its initiatives.

A Look at Gengos' Background

Before joining Terns, Andrew Gengos served as CFO at Athira Pharma, where he successfully navigated the financial landscape of the company. His track record includes serving as Chief Business Officer at Cyteir Therapeutics, successfully leading that entity to its public offering. Notably, Gengos has also held senior executive roles, including CEO positions at ImmunoCellular Therapeutics and Neuraltus Pharmaceuticals, leading strategic initiatives across diverse therapeutic areas.

About Terns Pharmaceuticals

Terns Pharmaceuticals is dedicated to creating therapies that address significant health challenges. Its pipeline encompasses multiple clinical-stage programs, each designed to tackle diseases such as oncology and obesity. Among these programs is an allosteric BCR-ABL inhibitor and a small-molecule GLP-1 receptor agonist, showcasing the Company’s commitment to innovation. With Gengos at the helm of its financial strategy, Terns includes a focus on continued development efforts, including a GIPR antagonist nominee aimed at transforming patient care.

Looking Ahead

Terns Pharmaceuticals stands at a promising juncture, with Andrew Gengos’ expertise expected to enhance its operational strategies and financial stability. The Company is well-positioned to make significant strides in the development of crucial therapies geared toward serious conditions. As they work together towards remarkable achievements in the future, stakeholders can anticipate continued updates on their clinical programs and corporate strategies.

Frequently Asked Questions

Who is Andrew Gengos?

Andrew Gengos is the newly appointed Chief Financial Officer of Terns Pharmaceuticals, bringing over 25 years of experience in finance and corporate strategy in the biotechnology sector.

What is Terns Pharmaceuticals' focus?

Terns Pharmaceuticals focuses on developing small-molecule therapies for serious diseases, specifically in the areas of oncology and obesity.

Why is the appointment of Andrew Gengos significant?

The appointment of Andrew Gengos is significant because his extensive experience in finance and corporate strategy positions him to help propel Terns Pharmaceuticals' growth and innovation.

What are the key programs at Terns Pharmaceuticals?

Terns' key programs include an allosteric BCR-ABL inhibitor and a small-molecule GLP-1 receptor agonist, among others, that target critical health issues.

How can I learn more about Terns Pharmaceuticals?

For more information about Terns Pharmaceuticals and its pipeline, visit their website at www.ternspharma.com.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Cardiovalve's Three-Year Data Clears a Crucial EU Hurdle

Updated Category News Views 98

A failing tricuspid valve is not a spreadsheet problem, and that matters before anybody gets carried away with a glossy conference presentation. Venus Medtech's Cardiovalve unit has reported results from TARGET in a population that was old, sick and largely out of good surgical options. That is precisely where a less invasive replacement therapy has to prove it can do...

Continue Reading
FASTEN Data Offers an Early Look at Ladera Closure

Updated Category News Views 137

Femoral access may be the unglamorous part of a valve procedure, but it is where an otherwise tidy case can turn ugly in a hurry. That makes Ladera Medical's full FASTEN data worth a careful look. The company reported results in 55 patients undergoing transfemoral TAVR/TAVI, and the numbers presented at London Valves 2026 suggest its large-bore closure system may address...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 534

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 666

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
AutoShop Answers Extends 2027 Training Into Fridays

Updated Category News Views 83

A repair bay can hum all day while the back office quietly bleeds profit. That unglamorous reality is why AutoShop Answers adding nine Friday specialty classes to its 2027 Key2Key Weekend calendar deserves a closer look. This is not a new tool chest or some vague motivational roadshow; it is an attempt to give independent shop owners an extra day to work on the pieces...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 410

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
DKSH's Vietnam Oncology Pact Carries Real Promise, Risk

Updated Category News Views 47

A cancer-market announcement ought to make investors pause before they reach for a spreadsheet. Specialised Therapeutics and DKSH have signed an exclusive partnership to bring oncology therapies into Vietnam, and the human case is painfully clear: the country recorded an estimated 180,000 new cancer cases and more than 120,000 deaths annually in the 2022 GLOBOCAN data....

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 607

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
CARsgen's CT1182 Data Opens a Careful New CAR-T Test

Updated Category News Views 126

Six very sick lymphoma patients are not a victory lap, but they can still make the whole cell-therapy field sit up straighter. CARsgen has disclosed first clinical results for CT1182, an in vivo CAR-T candidate built on its CARvivo platform, and the early package is plainly more interesting than the usual preclinical chest-thumping. The company reported three complete...

Continue Reading
Anthropic Bears Get New Tools, But Daily Risk Bites

Updated Category News Views 34

A $81.3 Billion Offering Invites Fast Money Anthropic arrived in public markets with the sort of numbers that make traders reach for both a calculator and a helmet. The company priced 980 million Class A shares at $83 on November 18, 2026, raising roughly $81.3 billion, then opened at $111.50 when it began Nasdaq trading on November 19. That is a monster debut by any...

Continue Reading

Top 5 Most Recently Viewed Articles

UROVO Launches Innovative Products to Transform Retail and Warehousing

Updated Category News Views 415

UROVO Launches Innovative Products to Transform Retail and Warehousing At EuroCIS 2025, UROVO, a leading name in industry applications, has unveiled four cutting-edge products: the UHF RFID Sled RFG91, Lightweight UHF RFID Handheld Reader DT50P Lite, Wireless Barcode Scanner K180, and Wearable Computer U2S. These innovations are set to revolutionize retail and warehouse...

Continue Reading
Ameren Corporation Launches New Stock Offering Initiative

Updated Category News Views 331

Ameren Corporation Unveils New Stock Offering In a strategic move to bolster its financial position, Ameren Corporation (NYSE: AEE) has announced the pricing of a significant underwritten offering of common stock. The company is set to offer 5,550,416 shares at an attractive public price of $94.00 each. This offering is aimed at facilitating various corporate financial...

Continue Reading
Exciting Developments: 2025 Bank of America Chicago Marathon

Updated Category News Views 224

Discover the 2025 Bank of America Chicago Marathon Lineup Chicago is gearing up for a thrilling marathon experience as the Bank of America Chicago Marathon announces its professional field for the upcoming event. Scheduled for 2025, the marathon promises to attract some of the world’s most elite runners, including notable champions from previous years. Elite Men Runners...

Continue Reading
Exploring Opportunities and Innovations at ASI Show 2025

Updated Category News Views 157

ASI Show 2025 Unveils Trends and Insights in Promotional Products The Advertising Specialty Institute just wrapped up an exciting event, showcasing the latest in promotional products and networking at the ASI Show 2025 in Fort Worth. Distributors and suppliers gathered from around the globe, eager to engage in meaningful discussions amidst challenges faced by the...

Continue Reading
Canada Nickel's Remarkable Nickel Mineralization Discovery

Updated Category News Views 139

Canada Nickel Announces Significant Exploration Results Canada Nickel Company Inc. (TSXV: CNC) is thrilled to share the latest updates from its exploration efforts at the Reid Nickel Sulphide Project. This recent phase of drilling has uncovered astonishing intervals of nickel mineralization, marking a pivotal moment for this promising mining venture. The discoveries are...

Continue Reading